243 results about "Proliferation activity" patented technology

The invention provides application of a turbellarian worm extract in preparation of a product for promoting wound healing, a biological agent for promoting the proliferation activity and / or migration ability of fibroblast NIH3T3, a biological agent for improving the wound healing rate and the decrustation time and a biological agent for improving the collagen fiber deposition type in the wound healing process. The biological preparation is used for promoting regeneration of skin appendage organs in the wound healing process. Wherein the extraction of the turbellarian worm extract comprises the steps of turbellarian worm cleaning, tissue crushing, alcohol extraction, centrifugal separation and concentration drying. The turbellarian worm extract has good capacity of promoting wound healing, and has the effects of effectively improving skin wound healing efficiency, shortening decrustation time, inhibiting scar formation in the wound healing process, promoting regeneration of skin appendage organs in the wound healing process and the like.

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The invention discloses a novel PARP / CK2 double-target kinase inhibitor small molecule as well as a pharmaceutical composition and application thereof, the small molecule takes benzofuran pyrimidone as a parent drug effect ring and a benzene ring as a connector in drug design, and is coupled with a 1-amino-2-methylisothiourea group, so that the novel PARP / CK2 double-target kinase inhibitor is obtained. The compound has good inhibitory activity on exogenous PARP enzyme, exogenous CK2 alpha enzyme and proliferation activity of various cancer cells, and can be used for preparing antitumor drugs. # imgabs0 #

The invention discloses a biological composite material as well as a preparation method and application thereof. The biological composite material comprises a decellularized biological amnion, mesenchymal stem cells and polypeptide hydrogel. In the polypeptide hydrogel, the sequence of the polypeptide is IGSRVGDRGDS. The biological composite material can effectively promote cell growth at a thin endometrial injury position, endometrial cell proliferation activity is higher, new vessel production related gene regulation activity is enhanced, fibrosis caused by the endometrial injury is well inhibited, re-adhesion after an intrauterine adhesion separation operation is prevented, and a good application prospect is achieved. The fertility is obviously improved, and the pregnancy rate is increased.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The present invention discloses an application of highly active human umbilical cord mesenchymal stem cells. HA-MSCs were isolated from human umbilical cord tissue using TeSR-E8 containing 5% CloneR and LN521-Coated culture flasks, and a technical system for HA-MSC isolation, expansion, and cryopreservation was established. Compared with conventionally cultured MSCs, the HA-MSCs prepared by the present invention have higher proliferation activity, smaller size, a higher nuclear-cytoplasmic ratio, and highly express embryonic stem cell-associated marker antigens SOX2, Nanog, and OCT4. They have the potential to differentiate into neural, myocardial, and hepato-intestinal progenitor cells derived from the three germ layers and possess excellent anti-aging activity.

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant polypeptide for improving the activity of bone marrow mesenchymal stem cells and application of the recombinant polypeptide. The amino acid sequence of the recombinant polypeptide is as shown in SEQ ID NO.3. The recombinant polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The recombinant polypeptide provided by the invention can promote the expression of the Ki67 gene and improve the proliferative activity of the bone marrow mesenchymal stem cells, also has the effect of inhibiting the replicative aging of the bone marrow mesenchymal stem cells, and has a wide application prospect.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 2, 4-disubstituted quinazoline derivative as well as a preparation method and application thereof. According to the invention, a series of 2, 4-disubstituted quinazoline derivative micromolecular ligands capable of acting on telomere G4 are developed on the basis of a quinazoline skeleton. The 2, 4-disubstituted quinazoline derivative disclosed by the invention has certain telomere G4 stability and telomere G4 binding capacity, better anti-tumor cell proliferation activity, low toxicity, higher cell membrane permeability and certain oral bioavailability, in addition, the 2, 4-disubstituted quinazoline derivative disclosed by the invention can activate congenital immune response of tumor cells, and can be used for preparing anti-tumor drugs. The compound has a wide prospect when being applied to preparation of anti-tumor drugs.

The present application relates to a kind of purine derivatives as the use of NSD2 and NSD3 inhibitor, the structural formula of the derivative is as shown in formula (I) or formula (II).The compound shows good NSD2, NSD3 inhibitory activity, can effectively reduce the methylation level of H3K36 in cell, and cause the reduction of cell proliferation activity of NSD2, NSD3 high expression tumor cell strain.

The invention discloses application of eleutheroside E in preparation of a medicine for preventing or treating hepatic fibrosis, and belongs to the technical field of biological medicine. The chemical name of the eleutheroside E is 4-[(1R, 3aS, 4S, 6aR)-4-[4-(beta-D-glucoside oxygen group)-3, 5-dimethoxy phenyl] tetrahydro-1H, 3H-furo [3, 4-c] furan-1-yl]-2, 6-dimethoxy phenyl-beta-D-glucoside, and the molecular formula of the eleutheroside E is C34H46O18. Researches find that the eleutheroside E has a remarkable effect of preventing or treating hepatic fibrosis diseases, does not have remarkable hepatotoxicity, and can be used for preparing the medicine for preventing or treating hepatic fibrosis. Cell experiment results show that the eleutheroside E can significantly reduce the proliferation activity of mouse hepatic stellate cells JS-1 and inhibit hepatic stellate cell activation, presents dose dependence and can be used for preparing the medicine for preventing or treating hepatic fibrosis.

The invention discloses a corrosion-resistant and collagen-functionalized magnesium-based metal coating and a preparation method of the corrosion-resistant and collagen-functionalized magnesium-based metal coating. Belongs to the technical field of biomedical material preparation. The preparation method comprises the following steps: firstly introducing hydroxyl into the surface of the magnesium alloy through alkali treatment, then sequentially dipping the magnesium alloy into a solution A and a solution B containing specific copolymers, drying to obtain an anti-corrosion coating, and finally coating with a recombinant humanized collagen solution. The copolymer A in the solution A and a magnesium substrate form a firm Si-O-Mg covalent bond through a silane coupling agent, and the fluorine-containing copolymer B in the solution B is tightly combined with a bottom layer through self-assembly, so that a super-hydrophobic anti-corrosion barrier with a stable structure and strong adhesion is constructed. The outermost collagen layer endows the magnesium alloy material with excellent endothelial cell adhesion and proliferation promoting activity. The multi-layer composite coating structure effectively solves the problems that magnesium alloy degradation is too fast, and an existing coating is weak in binding force and lacks biological functions, and has wide application prospects in implantable medical devices such as intravascular stents.

The invention discloses a preparation method of a three-dimensional umbilical cord mesenchymal stem cell exosome and application of the three-dimensional umbilical cord mesenchymal stem cell exosome in the fields of medicines and medical beauty. The preparation method comprises the step of amplifying umbilical cord mesenchymal stem cells (UC-MSCs) by adopting a three-dimensional culture system. Experiments show that IGF-1, EGF, VEGF, TGF-beta, PDGF, FGF and the like in the exosome subjected to three-dimensional culture are beneficial to skin repair and oxidation resistance, and the content of cell active factors for promoting collagen secretion is remarkably increased. The umbilical cord mesenchymal stem cell exosome significantly improves the fibroblast proliferation activity, and UV-induced skin fibroblast damage model construction and function verification experiments also prove that the exosome can promote the HA level recovery of damaged skin fibroblasts. The invention provides an efficient and safe biological material for tissue repair.

The invention belongs to the technical field of medicines, and particularly relates to bletilla striata polysaccharide hydrogel as well as a preparation method and application thereof. The BSP-MA / HA-NB hydrogel is prepared by screening the variety, dosage and preparation process of each component in the hydrogel, and the hydrogel is prepared from the following raw materials: methacrylated bletilla striata polysaccharide, o-nitrobenzaldehyde modified hyaluronic acid and the like. The adhesive property and the mechanical property of the hydrogel are obviously improved; the long-acting slow-release effect of the medicine components is achieved, the proliferation activity and migration ability of the bone marrow mesenchymal stem cells are promoted, and the bone marrow mesenchymal stem cells have good application prospects in the aspect of bone defect repair treatment.

The invention relates to the technical field of biological medicines, and provides application of ADRM1 gene / protein in preparation of a medicine for treating osteosarcoma. When the ADRM1 gene / protein is applied to the preparation of the medicine for treating osteosarcoma, the proliferation, migration and invasion capabilities of tumor cells can be remarkably inhibited, so that the occurrence and development of osteosarcoma are delayed. The expression of the ADRM1 is knocked down through an shRNA intervention technology, the mRNA and protein level of the ADRM1 in 143b and U2OS osteosarcoma cell lines can be remarkably reduced, the short-term proliferative activity and the long-term clone forming ability of the ADRM1 are further inhibited, and the migration and invasion characteristics of cells are effectively weakened. The growth of a tumor body formed after a nude mouse is inoculated with 143b osteosarcoma cells knocking down ADRM1 is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor body is reduced, which indicates that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of osteosarcoma.

The invention discloses a synthetic method of a C1-triazole oridonin derivative and an anti-tumor application of the C1-triazole oridonin derivative. The invention provides a synthetic method of the C1-triazole oridonin derivative, which comprises the following steps: carrying out four-step reaction to obtain an oridonin analogue containing an azide group at the C1 site, and catalyzing by cuprous iodide to obtain the C1-triazole oridonin derivative with the azide group at the C1 site, thereby obtaining the C1-triazole oridonin derivative with the azide group at the C1 site and the oridonin analogue with the azide group at the C1 site. According to the method, alkyne compounds containing different substituent groups react with C1-triazole oridonin to synthesize the C1-triazole oridonin derivative, the method is mild in condition and rapid in reaction, large-scale preparation of the C1-triazole oridonin derivative can be achieved, and the method is suitable for large-scale production of the C1-triazole oridonin derivative. Meanwhile, the C1-triazole oridonin derivative synthesized by the invention can be used for effectively inhibiting the proliferation activity of tumor cells and has a relatively good inhibition effect on MCF-7 cells and A549 cells.

The present invention relates to an isoindolinone derivative, a preparation method, a pharmaceutical composition and an application. The derivative is a compound of formula I or a pharmaceutically acceptable salt of the compound of formula I, wherein Ra is one of a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C6 alkyl; Rb and Rc are each one of a substituted or unsubstituted C1-C6 alkyl. Compared with the prior art, the isoindolinone derivative in the present invention has a novel structure, has significant anti-cancer cell proliferation activity, and the activities of multiple compounds are superior to those of doxorubicin.

An N-heterocycle-containing boric acid compound and a preparation method and application thereof are provided. The preparation method adopts 3-bromo-1-p-tosyl-1H-pyrrolo[2, 3-b]pyrimidine as a raw material to generate (3-((5-chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)boric acid by three steps of reaction. The (3-((5-chloro-4 (1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)boric acid has good inhibition effect on the proliferation activity of brain glioma, which is proven by cell experiments.

The invention relates to the field of chemical pharmacy, in particular to an aryl ketone derivative and furazan spliced conjugate as well as a preparation method and application thereof. The structural formula of the conjugate spliced by the aryl ketone derivative and the furazan is as shown in any one of formulas I-V: # imgabs0 # imgabs1 #. A coumarin skeleton is opened, and the conjugate spliced by the aryl ketone derivative and the furazan is designed and synthesized. The aryl ketone derivative and furazan combined conjugate disclosed by the invention is novel in structure, has the effect of highly selectively inhibiting the proliferation activity of P-gp overexpression drug-resistant tumor cells, and provides a new thought and direction for overcoming the multidrug resistance of the tumor cells caused by P-gp overexpression.

The application discloses a pyrrolobenzodiazepine-anthracene imide hybrid molecule and a preparation method and application thereof, and belongs to the technical field of chemical medicines. In order to solve the problems of few kinds of warheads of an existing antibody drug conjugate, single action mechanism and drug resistance easily generated in long-term use, a pyrrolobenzodiazepine-anthracene imide hybrid molecule shown in formula I and a preparation method and application thereof are provided. Experimental results show that the compound has strong anti-proliferation activity in various tumor cells such as ovarian cancer cells, gastric cancer cells and breast cancer cells, and an antibody drug conjugate thereof has good in-vivo and in-vitro anti-tumor activity and good safety.

The invention discloses application of phloretin in preparation of a medicine for promoting liver cell proliferation, and belongs to the technical field of medicine. A specific cell proliferation tracing system of the hepatocytes is utilized, the proliferation activity of the hepatocytes in an animal body can be continuously recorded, animal experiments find that in the physiological homeostasis maintaining process of a mouse, phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of liver tissue, and it is found through hepatic lobule zoning analysis that phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of the liver tissue. The phloretin can effectively promote proliferation of hepatic cells in the first, second and third regions of the hepatic lobule. Therefore, phloretin is a potential medicine for liver regeneration.

The invention discloses an effect of deuterium-depleted water on continuous growth of human mesenchymal stem cells, and belongs to the field of biomedicine. The invention relates to a medicine for promoting the growth of human mesenchymal stem cells. The medicine comprises deuterium-depleted water with the concentration of 25-50 ppm. On the other hand, the invention further relates to application of the deuterium-depleted water in preparation of drugs for promoting growth of human mesenchymal stem cells. Compared with the prior art, the invention discloses the effect of the deuterium-depleted water on the human mesenchymal stem cells, specifically, the deuterium-depleted water is used for improving the proliferation capacity or proliferation activity of the human mesenchymal stem cells, and the deuterium-depleted water is used for preparing the deuterium-depleted water for prolonging the life of the human mesenchymal stem cells and promoting the single cell clone formation capacity of the human mesenchymal stem cells. And a new research and development direction is provided for repairing and culturing human mesenchymal stem cells.

The application discloses a dihydroquinazolinone-containing N-hydroxy amide compound and a preparation method and application thereof, relates to the technical field of medicinal chemistry, and utilizes the splicing principle to design and synthesize dihydroquinazolinone-containing N-hydroxy amide compounds with novel structures, and the compounds are tested in terms of HDAC6 protein affinity and anti-proliferation activity of cervical cancer cell Siha, and the results show that the compounds E1-E5 have better affinity to the HDAC6 protein, the IC 50 values are 4.1-85.4 nM, wherein the affinity of the compound E4 to the HDAC6 protein is higher than that of a positive control SAHA; and the compounds E1-E5 can better inhibit the proliferation of the cervical cancer cell Siha, the IC 50 values are 2.4-9.3 muM, wherein the activity of the compound E4 is the strongest.

The invention belongs to the technical field of organoids, and particularly relates to a method for evaluating the influence of intervention measures such as drugs on the proliferation capacity of intestinal stem cells through proliferation indexes of the organoids and application of the method. The invention discloses a kit for efficiently, simply, conveniently and effectively culturing and constructing intestinal organs and evaluating the multiplication capacity of intestinal stem cells, which can better fit in-vivo tissues and cell microenvironments, as well as a method and application of the kit. The method can be used for detecting the influence of different intervention measures on the proliferation activity of the small intestine stem cells more accurately and more stably, and is beneficial to deeply researching and developing new drugs and researching the drug sensitivity and the drug action mechanism.

The invention discloses an organoid culture medium, a kit and a method for culturing an organoid, and relates to the technical field of organoid culture. The organoid culture medium provided by the invention can improve the proliferation activity of the organoid, a relatively complete organoid form can be obtained through culture, and the cost of the culture medium is reduced. The tumor cell organoid obtained by adopting the organoid culture medium provided by the invention has a more complete tumor cell surface marker, and the cell damage is smaller.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The invention relates to an HDAC1 inhibitor and a preparation method and application thereof. The HDAC1 inhibitor has a structure as shown in a formula (1). The compound shown in the formula (1) shows strong inhibitory activity on HDAC1 protease, and the IC50 value of the compound is basically smaller than 100 nM. Meanwhile, the compound disclosed by the invention also shows strong anti-proliferative activity for MC-38 tumor cells, and the IC50 value of the compound is basically less than 1 mu M, so that the compound disclosed by the invention is expected to be prepared into medicines for treating various HDAC1-mediated related diseases.

The invention belongs to the field of pharmaceutical chemicals, and discloses preparation of a tricyclic heterocyclic derivative and application of the tricyclic heterocyclic derivative as an antitumor drug. The structure of the tricyclic heterocyclic derivative is # imgabs0 #. The invention provides a pharmaceutical composition containing the tricyclic heterocyclic derivative and a pharmaceutically acceptable salt, a solvate, an isotope derivative or a prodrug thereof. The invention aims to provide a preparation containing the tricyclic heterocyclic derivative, and a pharmaceutically acceptable salt, a solvate, an isotope derivative or a prodrug of the tricyclic heterocyclic derivative. Various in-vitro tumor cell line tests prove that the compounds have remarkable anti-tumor cell proliferation activity.

The present application belongs to the field of medicinal chemistry and pharmacotherapy, and particularly relates to a chalcone mannich base compound, a pharmaceutical composition and a preparation method and application thereof. The present application takes paeonol as a raw material, and obtains corresponding 3-substituted and 5-amino-methyl-substituted paeonol mannich base through mannich reaction of paeonol, polyoxymethylene and different organic amines. After the 3-substituted and 5-substituted paeonol mannich base is separated through column chromatography, the chalcone mannich base compound is obtained through Claisen-Schmidt reaction of the 3-substituted and 5-substituted paeonol mannich base and benzaldehyde containing different substituents. Experiments prove that the chalcone mannich base compound improves the physical and chemical properties of the chalcone mannich base and improves the drug efficacy, can solve the problem of poor water solubility, and has good anti-tumor cell proliferation activity.

The invention belongs to the technical field of medicines, and relates to an amide compound based on a hydrophobic labeling technology and preparation and application thereof. The structural general formula H of the target product is shown in the specification, or pharmaceutically acceptable salts, solvent compounds or hydrates of the target product. The compound provided by the invention has dual mechanisms of inhibiting polymerization and degradation of tubulin, has an effect of inhibiting tumor proliferation, and has a good prospect in the aspect of development of antitumor drugs.

The application relates to the field of biological medicine, and provides application of ADRM1 gene / protein in preparation of a drug for treating osteosarcoma. The ADRM1 gene / protein is applied to preparation of the drug for treating osteosarcoma, can significantly inhibit proliferation, migration and invasion ability of tumor cells, and thus delays occurrence and development of the osteosarcoma. By shRNA intervention technology, the expression of ADRM1 is knocked down, the mRNA and protein levels of ADRM1 in 143b and U2OS osteosarcoma cell lines are significantly reduced, short-term proliferation activity and long-term clone formation ability are inhibited, and migration and invasion characteristics of the cells are effectively weakened. After 143b osteosarcoma cells with the knocked-down ADRM1 are inoculated into nude mice, the growth of the tumor formed by the cells is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor is down-regulated, indicating that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of the osteosarcoma.